Indaptus Therapeutics, Inc. Retained Earnings
Indaptus Therapeutics, Inc. (INDP) had Retained Earnings of -$85.62 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$85.62M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$83.83M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$81.29M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$73.18M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$85.62M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$83.83M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | -$81.29M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$73.18M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$70.20M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$64.97M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$60.44M 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$56.31M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$53.24M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$49.22M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | -$45.42M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$41.41M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | -$37.49M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$34.25M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$29.99M 10-K · filed 2024-03-13 | |
| 2022-09-30 | -$26.34M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$22.87M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$19.04M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$15.67M 10-K · filed 2023-03-17 | |
| 2021-09-30 | -$12.45M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$215.21M 10-Q · filed 2021-08-16 | |
| 2020-12-31 | -$7.96M 10-K · filed 2022-03-21 | -$203.55M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |